BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20230312T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20231105T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20240310T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20241103T090000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20250309T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20251102T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Denver
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20230312T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20231105T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20240310T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20241103T080000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0700
TZOFFSETTO:-0600
TZNAME:MDT
DTSTART:20250309T090000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0600
TZOFFSETTO:-0700
TZNAME:MST
DTSTART:20251102T080000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:Europe/Zurich
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20240201T120000
DTEND;TZID=Europe/Paris:20240201T130000
DTSTAMP:20240125T192454Z
CREATED:20240125T192454Z
LAST-MODIFIED:20240125T192454Z
UID:59695-1706788800-1706792400@globalbiodefense.com
SUMMARY:WHO Update on COVID-19
DESCRIPTION:A World Health Organization (WHO) update on COVID-19 will be held 1 February 2024 via an EPI-WIN webinar. \nCOVID-19 remains a major public health concern. WHO experts will address what variants are circulating\, their risk and impact\, and what can be done to prevent and protect against infections\, severe disease\, post-COVID-19 condition and deaths. The experts will also address common concerns from the public. \nSpeakers: \n\nDr Maria Van Kerkhove\, Director (a.i.)\, Department of Epidemic and Pandemic Preparedness and Prevention (EPP)\, WHO\nDr Janet Diaz\, Unit Head\, Clinical Management\, WHO\nDr Lorenzo Subissi\, Technical Officer\, EPP\, WHE\, WHO (TBC)\nMs Vicky Houssiere\, Technical Officer\, Risk Communication and Community Engagement (RCCE)\, WHE\, WHO\nMs Shagun Khare\, Communications Officer\, WHE\, WHO\n\nPlease visit the EPI-WIN webinar: WHO update on COVID-19 event page to register. This webinar will be livestreamed on the WHO YouTube channel.
URL:https://globalbiodefense.com/event/who-update-on-covid-19/
LOCATION:https://who.zoom.us/webinar/register/WN_ULS7nOrqRCaw2H9lUZmO7w#/registration
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240202
DTEND;VALUE=DATE:20240203
DTSTAMP:20240201T190248Z
CREATED:20240201T190201Z
LAST-MODIFIED:20240201T190248Z
UID:59787-1706832000-1706918399@globalbiodefense.com
SUMMARY:Meeting of the Committee on the Current State of Research\, Development\, and Stockpiling of Smallpox Medical Countermeasures
DESCRIPTION:This is a closed session\, virtual meeting of the Committee on the Current State of Research\, Development\, and Stockpiling of Smallpox Medical Countermeasures. \nThe meeting is an activity of an ad hoc committee of the National Academies of Sciences\, Engineering\, and Medicine charged with conducting a study to examine lessons learned from the recent COVID-19 pandemic and mpox multi-country outbreak to inform an evaluation of the current state of research\, development\, and stockpiling of smallpox medical countermeasures (MCMs). \nThe committee will consider how the COVID-19 pandemic and the mpox multi-country outbreak can inform improvements to smallpox readiness and response\, including the availability of smallpox MCMs and the ability to meet potential demand. \nThe committee will further examine the current state of MCMs for the diagnosis\, prevention\, and treatment of smallpox\, including: \n\nHow the mpox outbreak altered assumptions about the efficacy and utility of smallpox MCMs\nThe continued role of live Variola virus for research and public health purposes\nImplications for the composition of smallpox MCMs in the U.S. Strategic National Stockpile (SNS)\n\nThe benefits and risks of scientific and technological advances on smallpox readiness and response will be addressed and the committee will identify key priorities in research and development of smallpox MCMs. \nBuilding on the Institute of Medicine’s previous reports\, Assessment of Future Scientific Needs for Live Variola Virus (1999) and Live Variola Virus: Considerations for Continuing Research (2009)\, and a review of existing literature\, analyses\, and other expert and public input\, the committee will develop a report with its findings and conclusions on priorities for additional research or activities to improve the U.S. Government readiness and response posture against smallpox\, and on the composition of the SNS to ensure appropriate smallpox MCM response options. \nPlease visit the National Academies’ Meeting 5 of the Committee on the Current State of Research\, Development\, and Stockpiling of Smallpox Medical Countermeasures event page for more information.
URL:https://globalbiodefense.com/event/meeting-of-the-committee-on-the-current-state-of-research-development-and-stockpiling-of-smallpox-medical-countermeasures/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Denver:20240205T170000
DTEND;TZID=America/Denver:20240205T183000
DTSTAMP:20240202T221754Z
CREATED:20240202T221754Z
LAST-MODIFIED:20240202T221754Z
UID:59867-1707152400-1707157800@globalbiodefense.com
SUMMARY:Investigating Public Health Mysteries in a Globalized World
DESCRIPTION:The Scowcroft Institute of International Affairs at the Bush School of Government & Public Service at Texas A&M University will host Katherine Eban as she discusses “Investigating Public Health Mysteries in a Globalized World” on February 5\, 2024\, at 5:30 p.m. at the Annenberg Presidential Conference Center. \nAmericans want high-quality\, affordable medication and safety from infectious diseases. But those public health goals are increasingly impacted by far-distant events\, and far different regulatory cultures from our own. Katherine Eban\, an award-winning investigative journalist\, will describe the challenges and rewards of investigating big public health stories that have international and national security repercussions. \nAbout the speaker: \nKatherine Eban \nKatherine Eban\, an investigative journalist\, is a Vanity Fair special correspondent and Andrew Carnegie fellow. Her reporting on generic drug fraud\, gun trafficking\, coercive CIA interrogations\, and COVID-19’s origins has won international attention and numerous awards\, including from the National Association of Science Writers\, the Overseas Press Club\, Investigative Reporters & Editors and Newswomen’s Club of New York. Her 2019 book\, Bottle of Lies: The Inside Story of the Generic Drug Boom\, was a New York Times bestseller. A Rhodes Scholar educated at Brown University and Oxford University\, she lives in New York with her husband\, two daughters and Newfoundland dog\, Romeo. \nPlease visit the Texas A&M Bush School of Government & Public Service’s Investigating Public Health Mysteries in a Globalized World event page to RSVP.
URL:https://globalbiodefense.com/event/investigating-public-health-mysteries-in-a-globalized-world/
LOCATION:Annenberg Presidential Conference Center\, 1002 Bush Drive West\, College Station\, TX\, 77845\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240206
DTEND;VALUE=DATE:20240208
DTSTAMP:20240201T205734Z
CREATED:20240201T202039Z
LAST-MODIFIED:20240201T205734Z
UID:59796-1707177600-1707350399@globalbiodefense.com
SUMMARY:Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions - Third Meeting
DESCRIPTION:This is the third meeting of the committee of experts and will be conducted virtually. The meeting will include a closed and public session. There will be an opportunity for interested stakeholders to share public comments with the committee on February 7\, 2024 at 12:00 p.m. \nPublic comments will provide the committee with additional insight into key issues related to the study’s statement of task. These include\, but are not limited to: \n\nThe use of regulatory flexibilities and supplementary data (e.g.\, natural history studies and patient registries) when evaluating the safety and efficacy of drugs for rare diseases and conditions\nFDA and EMA engagement of people with lived experience when developing guidance\, policies\, and programs.\n\nPublic comments\, alongside other materials stakeholders have shared\, will be reviewed by the committee\, and may help inform committee deliberations on the statement of task. All comments and materials shared with the committee will be made publicly available in accordance with institutional policies. \nPlease visit NASEM’s Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union event page for more information on public comments for this meeting. \nOPEN SESSION AGENDA HIGHLIGHTS \n\nLongitudinal trial design\nMaster protocols for drug development trials\nExternal controls for drug development trials\nConsiderations for pediatric trials: caregiver perspective\nConsiderations for pediatric trials: regulatory science perspective\nConsiderations for pediatric trials: industry perspective\nExpanded access programs\nPatient registries and natural history data\nPatient experience data\nModel-informed drug development\nAnalysis methods – causal inference\nFlexibilities applied at FD\n\nABOUT THE COMMITTEE \nIn response to a Congressional request\, an ad hoc committee of the National Academies of Sciences\, Engineering\, and Medicine is conducting a study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. \nThe committee will evaluate: \n\nFlexibilities\, authorities\, or mechanisms available to regulators in the United States and the European Union applicable to rare diseases or conditions;\nThe consideration and use of supplemental data submitted during review processes in the United States and the European Union\, including data associated with open label extension studies and expanded access programs specific to rare diseases or conditions.\nAn assessment of collaborative efforts between United States and European Union regulators related to: product development programs under review; policies under development and those recently issued; and scientific information related to product development or regulation.\n\nBased on its information gathering and internal deliberations\, the committee will develop a report with its findings\, conclusions\, and recommendations for actions that Congress\, federal agencies\, the pharmaceutical industry\, and nongovernmental organizations can take to support collaborative efforts. \nPlease visit the National Academies’ Processes to Evaluate the Safety and Efficacy of Drugs for Rare Diseases or Conditions in the United States and the European Union event page for more information. \nThe Fourth Meeting of the committee will be held 3-4 April 2024. \nThe Fifth Meeting of the committee will be held 23-24 May 2024.
URL:https://globalbiodefense.com/event/processes-to-evaluate-the-safety-and-efficacy-of-drugs-for-rare-diseases-or-conditions-in-the-united-states-and-the-european-union/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240207T100000
DTEND;TZID=America/New_York:20240207T110000
DTSTAMP:20240125T183458Z
CREATED:20240125T182836Z
LAST-MODIFIED:20240125T183458Z
UID:59690-1707300000-1707303600@globalbiodefense.com
SUMMARY:What's Next for the Pandemic Financing Agenda?
DESCRIPTION:A virtual event featuring an expert panel focused on What’s Next for the Pandemic Financing Agenda? will be held 7 February 2024. \nAs the world approaches the four-year anniversary of the start of the COVID-19 pandemic\, questions remain as to whether we are more prepared and ready than before. A recently published CGD working paper indicated a substantial risk of occurrence of future pandemics. Yet the financing tools for preparedness and response remain immature\, if not neglected. The world still needs faster\, larger\, and clearer financing tools for pandemics. In this webinar\, we review the ongoing problem of gaps in the global pandemic risk financing architecture in the aftermath of the G20 Pandemic Financing report and G7 Nagasaki Health Ministers’ Communiqué\, and propose specific policy recommendations for world leaders and multilateral and bilateral donors to consider in 2024. \nSPEAKERS \n\nRuchir Agarwal\, Research Fellow\, Harvard Kennedy School; Non-resident Fellow\, Center for Global Development\nNita Madhav\, Senior Director\, Head of Epidemiology & Modeling\, Ginkgo Bioworks\nCarolyn Reynolds\, Co-Founder\, Pandemic Action Network\nCristina Stefan\, Lead Risk Finance Advisor\, Centre for Disaster Protection\n\nMODERATOR \n\nVictoria Fan\, Senior Fellow\, Center for Global Development\n\nThe virtual event\, co-hosted by CGD\, Ginkgo Bioworks\, the Pandemic Action Network\, and the Centre for Disaster Protection\, will begin with short presentations from each speaker\, followed by a discussion among the panelists and an audience Q&A. \nPlease visit the What’s Next for the Pandemic Financing Agenda? event page to register and for more information. \n 
URL:https://globalbiodefense.com/event/whats-next-for-the-pandemic-financing-agenda/
LOCATION:https://www.youtube.com/watch?v=SEyOTTRAyD8
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240208
DTEND;VALUE=DATE:20240209
DTSTAMP:20240201T184853Z
CREATED:20240201T184853Z
LAST-MODIFIED:20240201T184853Z
UID:59785-1707350400-1707436799@globalbiodefense.com
SUMMARY:Enhancing Biotechnology Innovation and Applications for National Security – First Meeting of Experts
DESCRIPTION:The National Academies will convene a meeting of experts on 8 Feb 2024 to focus on ways to foster a research and development network in the United States that drives biotechnology innovation and applications. \nThis meeting will be held in a hybrid setting (Washington DC and online). \nThis is the first of a series of meetings of experts\, organized under the auspices of the Standing Committee on Advances and National Security Implications of Transdisciplinary Biotechnology\, which will bring together gatherings of cross-sector experts to discuss key topics at the intersection of national security and transdisciplinary biotechnology research and development. \nThe forthcoming second meeting of experts will focus on understanding future defense needs and ways to communicate those needs to the research community.  The third meeting of experts will focus on understanding the regulatory processes and needs in the United States to enhance development of innovative biotechnologies for defense and subsequently\, to transition defense-specific biotechnologies and services to other sectors. \nEach meeting will highlight how more general concepts relate to specific biotechnologies using two illustrative examples: \n\nUse of artificial intelligence in biotechnology research and development\nExperimental/laboratory automation in biotechnology and development\n\nThe effort is sponsored by the National Security Commission on Emerging Biotechnology. \nPlease visit the  Enhancing Biotechnology Innovation and Applications for National Security – First Meeting of Experts.
URL:https://globalbiodefense.com/event/enhancing-biotechnology-innovation-and-applications-for-national-security-first-meeting-of-experts/
LOCATION:National Academies of Sciences\, 2101 Constitution Ave NW\, Washington\, DC\, 20418\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240208T080000
DTEND;TZID=America/New_York:20240208T170000
DTSTAMP:20240201T220044Z
CREATED:20240201T215837Z
LAST-MODIFIED:20240201T220044Z
UID:59814-1707379200-1707411600@globalbiodefense.com
SUMMARY:Why Indoor Chemistry Matters Prioritizing Indoor Chemistry Research - Workshop 2
DESCRIPTION:A National Academies committee of experts on Emerging Science on Indoor Chemistry will meet for a workshop on 8 February 2024 to discuss ways to support and prioritize indoor chemistry research. \nThe event is a hybrid in-person (Washington DC) and virtual format. \nThis event aims to discuss the following topics: \n\nOutcomes and recommendations from the National Academies consensus report Why Indoor Chemistry Matters.Special focus will be given to Recommendation 8 “ Given the challenges\, complexity\, knowledge gaps\, and importance of indoor chemistry\, federal agencies and others that fund research should make the study of indoor chemistry and its impact on indoor air quality and public health a national priority”.\nEmerging or impactful areas of indoor chemistry research.\nExamine current funding opportunities available for indoor chemistry research; identify how sustained support for the field can be achieved in the near future.\nA major goal on this workshop is to encourage more partnerships with funding agencies\, foundations\, and NGOs to strengthen investment in indoor chemistry research.\n\nHighlighted agenda topics include: \nWhy Indoor Chemistry Matters: Select Recommendations \n\nVicki H. Grassian\, PhD\, Chair\, Department of Chemistry and Biochemistry\, University of California\, San Diego\n\nAssessing Chemical Complexity in Indoor Environments \n\nJonathan Abbatt\, PhD\, Professor\, University of Toronto\nRobin E. Dodson\, ScD\, Associate Director of Research Operations and Research Scientist\, Silent Spring Institute\nVito Ilacqua\, PhD\, Acting Director of the Center for Scientific Analysis\, Office of Radiation and Indoor Air (ORIA)-Office of Air and Radiation (OAR)\, U.S. Environmental Protection Agency\nXiaoyu Liu\, PhD\, Senior Physical Scientist\, U.S. Environmental Protection Agency\nBarbara Turpin\, PhD\, Professor\, University of North Carolina\, Chapel Hill\n\nGermicidal UV Radiation\, Unintended Chemistry: \n\nDelphine Farmer\, PhD\, Professor\, Colorado State University\nMichael F. Link\, Physical Scientist\, Engineering Laboratory\, National Institute of Standards and Technology (NIST)\nPaula Olsiewski\, PhD\, Contributing Scholar\, Johns Hopkins Center for Health Security\nRichard Williamson\, Program Director\, Far-UVC\, Blueprint Biosecurity\n\nHow Do we Strengthen the Handshake Between IAQ and Exposure Science/Cognition\, Health and Well-Being: \n\nAntonia Calafat\, PhD\, Chief\, Organic Analytical Toxicology Branch\, Centers for Disease Control and Prevention\nElaine Cohen-Hubal\, PhD\, Senior Science Advisor\, U.S. Environmental Protection Agency\nLCDR Jason Ham\, PhD\, Research Scientist\, Health Effects Laboratory Division (HELD)\, Chemical and Biological Monitoring Branch (CBMB)\, National Institute for Occupational Safety and Health (NIOSH)\nKrystal Pollitt\, PhD\, PEng\, Associate Professor of Epidemiology\, Yale School of Public Health (YSPH)\nTreye Thomas\, PhD\, Lead Toxicologist and Program Manager\, Chemicals\, Nanotechnology and Emerging Materials (CNEM) Program\, Office of Hazard Identification and Reduction\, Consumer Product Safety Commision (CPSC\n\nBuildings Impact on Chemistry \n\nMark Hernandez\, PhD\, Professor\, University of Colorado\, Boulder\nJeffrey Siegel\, PhD\, Professor\, University of Toronto\nBrett Singer\, PhD\, Staff Scientist and Principal Investigator (PI)\, Energy Technologies Area\, Lawrence Berkeley National Laboratory\nDavid Rowson\, Director Indoor Environments Division\, Environmental Protection Agency\nBrian Gilligan\, PEng\, SCPM \, Deputy Director\, Office of Federal High Performance Green Buildings\, General Services Administration\n\nRESOURCES: \nWhy Indoor Chemistry Matters (2022) \nPeople spend the vast majority of their time inside their homes and other indoor environments where they are exposed to a wide range of chemicals from building materials\, furnishings\, occupants\, cooking\, consumer products\, and other sources. Despite research to date\, very little is known about how exposures to indoor chemicals across complex chemical phases and pathways affect human health. The COVID-19 pandemic has only increased public awareness of indoor environments and shed light on the many outstanding questions about how best to manage chemicals indoors. \nPROJECT GOALS: \nThis study will examine the state of science regarding chemicals in indoor air. A team of scientific experts will focus on under-reported chemical science discoveries and how these findings shine light on the link between chemical exposure\, air quality\, and human health. The final report will explore potential opportunities for new scientific research. It will also identify what research will be most critical to understanding the chemical composition of indoor air and adverse exposures. The environments in this study will be limited to non-industrial exposure within buildings. \nPlease visit the Why Indoor Chemistry Matters Workshop 2: Prioritizing Indoor Chemistry Research event page to register.
URL:https://globalbiodefense.com/event/why-indoor-chemistry-matters-prioritizing-indoor-chemistry-research-workshop-2/
LOCATION:National Academies of Sciences\, 2101 Constitution Ave NW\, Washington\, DC\, 20418\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240215T110000
DTEND;TZID=America/New_York:20240215T160000
DTSTAMP:20240202T000503Z
CREATED:20240202T000503Z
LAST-MODIFIED:20240202T000503Z
UID:59822-1707994800-1708012800@globalbiodefense.com
SUMMARY:Forum on Medical and Public Health Preparedness for Disasters and Emergencies
DESCRIPTION:The Forum on Medical and Public Health Preparedness for Disasters and Emergencies will convene again on 15 February 2024. \nIn this meeting\, Forum members will: \n\nIdentify the seminal social and behavioral sciences (SBS) lessons learned from COVID-19 and other past public health emergencies\nExplore how SBS lessons\, concepts\, and theories can be leveraged to inform and be incorporated in future medical and public health preparedness and response efforts\nDiscuss receive updates\, and provide input on current and planned Forum activities and other National Academies activities of interest.\n\nFormed in 2007\, the Forum on Medical and Public Health Preparedness for Disasters and Emergencies convenes and engages leaders at federal\, state\, local\, tribal\, and territorial levels representing government\, non-profit\, and for-profit sectors to improve the nation’s medical and public health preparedness for\, response to\, and recovery from disasters and emergencies\, including emerging threats. \nRecent work of the Forum includes: \n\nMedical Countermeasures- Expanding Delivery and Increasing Uptake Through Public-Private Partnerships\nFuture of the Nation’s Laboratory Systems for Health Emergency Response\n Future Planning for the Public Health Emergency Preparedness Enterprise: Lessons Learned from the COVID-19 Pandemic\nApplying Lessons Learned from COVID-19 Research and Development to Future Epidemics\nAccelerating the Development and Uptake of Rapid Diagnostics to Address Antibiotic Resistance\nEvolving Crisis Standards of Care and Lessons Learned\nCOVID-19: Disaster Preparedness and Vulnerable Populations\nEnhancing Private Sector Readiness for 21st Century Health Threats\nEngaging Private Sector Healthcare Systems in Building Capacity to Respond to Threats to the Public’s Health and National Security\nThe Future of Disaster Health Volunteerism\n\nPlease visit the National Academies’ Forum on Medical and Public Health Preparedness for Disasters and Emergencies – February 2024 Meeting  website for more information. \n 
URL:https://globalbiodefense.com/event/forum-on-medical-and-public-health-preparedness-for-disasters-and-emergencies/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240215T120000
DTEND;TZID=America/New_York:20240215T130000
DTSTAMP:20240125T224115Z
CREATED:20240125T223922Z
LAST-MODIFIED:20240125T224115Z
UID:59701-1707998400-1708002000@globalbiodefense.com
SUMMARY:The Clear and Present Threat of Chem-Bio and Data and Cyberscientific and Technological (CB-DCST) Tools and Techniques
DESCRIPTION:The Homeland Defense & Security Information Analysis Center (HDIAC) will host a webinar on The Clear and Present Threat of Chem-Bio and Data and Cyberscientific and Technological (CB-DCST) Tools and Techniques on 15 February 2024. \nGiven the current global shift toward symmetrical warfare\, major powers and nonstate proxies are developing radical leveling and emerging technology for use as “deterrence leveraging” in nonkinetic and kinetic engagements. \nAlthough regnant treaties and conventions are postured to govern chemical and biological weapons\, novel advances in genetics\, synthetic biology\, and neuroscience can enable side-stepping such international regulatory constraints when coupled with big data and cyberscientific tools and methods. These advances can also afford rapid scientific and technological progress in ways that pose a clear and present threat to global biosecurity and defense. \nIn this webinar\, Dr. James Giordano will present an overview of current and emerging developments in CB-DCST; describe trajectories for their deterrent applications in nonkinetic and/or kinetic engagements; address ethico-legal issues relevant to their research\, use\, and governance; and propose a paradigm for realistic approach to informing surveillance\, forecasting\, and regulatory control. \nABOUT THE SPEAKER : Dr. James Giordano\, Ph.D.\, MPhil \nDr. James Giordano is Pellegrino Center professor of neurology and biochemistry\, chief of the Neuroethics Studies Program\, and codirector of the Project on Brain Science and Global Health Law and Policy at Georgetown University Medical Center. He serves as senior bioethicist of the Defense Medical Ethics Center\, Uniformed Services University of Health Sciences; Stockdale distinguished fellow of science\, technology\, and ethics at the U.S. Naval Academy; and non-resident senior fellow of the Simon Center for the Professional Military Ethic at the U.S. Military Academy\, West Point\, NY. \nPlease visit HDIAC’s The Clear and Present Threat of Chem-Bio and Data and Cyberscientific and Technological (CB-DCST) Tools and Techniques on 15 February 2024.
URL:https://globalbiodefense.com/event/the-clear-and-present-threat-of-chem-bio-and-data-and-cyberscientific-and-technological-cb-dcst-tools-and-techniques/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240222
DTSTAMP:20240207T184247Z
CREATED:20240207T184123Z
LAST-MODIFIED:20240207T184247Z
UID:59952-1708387200-1708559999@globalbiodefense.com
SUMMARY:CWMD/MCDC Winter Medical & WMD Countermeasure Symposium
DESCRIPTION:The CWMD/MCDC: 2024 Winter Medical & WMD Countermeasure Symposium will be held 20-21 February 2024 in Baltimore\, Maryland. \nHosted by the Countering Weapons of Mass Destruction Consortium (CWMD) and the Medical CBRN Defense Consortium (MCDC)\, the event will feature sessions to interact with leads from key programs\, for example: \n\nJPEO Futures\nJoint Project Leads (JPL) PL Enabling Biotechnologies (EB)\nJoint Project Managers (JPM) Special Operations Forces (SOF)\nJoint Project Managers (JPM) Protection\n\nPoster Registration Deadline is 14 February. \nABOUT THE CWMD CONSORTIUM \nThe Countering Weapons of Mass Destruction (CWMD) Consortium is a well-established community of industry\, academia and government focused on rapid prototyping and maturing countering WMD efforts and CBRNE hazard awareness. Through an Other Transaction Agreement with the JPEO-CBRND (Joint Program Executive Office for Chemical\, Biological\, Radiological and Nuclear Defense)\, the CWMD Consortium is accomplishing the counter WMD related prototyping needs of any federal agency. \nThe CWMD scope spans development of PPE\, detection systems\, sensors\, other protection needs\, and situational awareness. These address consequence management/hazard mitigation; threats/vulnerabilities awareness and counter-proliferation technologies/capabilities; arms control technologies; experimentation of emerging technologies and CBRNE technologies to deliver capabilities to the warfighter. \nABOUT THE MEDICAL CBRN DEFENSE CONSORTIUM \nThe Medical CBRN Defense Consortium (MCDC) is a well-established community of industry\, academia\, and government focused on rapid prototyping and maturing medical countermeasures to prevent\, detect and treat exposure to CBRN threats. Through an Other Transaction Agreement with the JPEO-CBRND (Joint Program Executive Office for Chemical\, Biological\, Radiological and Nuclear Defense)\, the MCDC is developing life-saving medical pharmaceutical\, diagnostics and therapeutics to safe-guard and enhance the mission effectiveness of our soldiers. \nThe MCDC scope spans development of medical countermeasure prototypes to include vaccines (COVID-19\, Marburg\, Ebola\, VEE\, VEEV\, Botulinum\, etc.)\, therapeutics (COVID-19\, SNAPP\, small molecule antivirals\, OPNAs\, Smallpox\, MDR Bacterial bio threat pathogens\, Tularemia\, etc.)\, detection/diagnostics (Meliodiosis\, Plague\, CRISPR-based\, man-portable diagnostics systems\, antibody platforms\, etc.)\, autoinjectors (Scopolamine\, Naloxone\, Diazepam\, etc.) and other needs. \nPlease visit the Medical CBRN Defense Consortium site for more information or register here for the CWMD/MCDC Winter Medical & WMD Countermeasure Symposium.
URL:https://globalbiodefense.com/event/cwmd-mcdc-winter-medical-wmd-countermeasure-symposium/
LOCATION:Baltimore Marriott Waterfront\, 700 Aliceanna St\, Baltimore\, MD\, 21202\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240220
DTEND;VALUE=DATE:20240228
DTSTAMP:20240219T192805Z
CREATED:20240202T233915Z
LAST-MODIFIED:20240219T192805Z
UID:59870-1708387200-1709078399@globalbiodefense.com
SUMMARY:The 38th Annual AAAI Conference on Artificial Intelligence
DESCRIPTION:The AAAI-24 Annual Conference on Artificial Intelligence will be held 20-27 February in Vancouver\, Canada. \nThe purpose of the AAAI conference series is to promote research in Artificial Intelligence (AI) and foster scientific exchange between researchers\, practitioners\, scientists\, students\, and engineers across the entirety of AI and its affiliated disciplines. AAAI-24 will feature technical paper presentations\, special tracks\, invited speakers\, workshops\, tutorials\, poster sessions\, senior member presentations\, competitions\, and exhibit programs\, and a range of other activities to be announced. \nHighlighted topics and presentations include: \n\nML+Optimization: Driving Social Impact in Public Health and Conservation\nDeploying ADVISER : Impact and Lessons from using Artificial Intelligence for Child Vaccination Uptake in Nigeria\nOutlier Ranking for Large-Scale Public Health Data\nGeometric ML: from Euclid to Drug Design\nGenerating Novel Leads for Drug Discovery Using LLMs with Logical Feedback\nAngle Robustness Unmanned Aerial Vehicle Navigation in GNSS-Denied Scenarios\nGeometric-Facilitated Denoising Diffusion Model for 3D Molecule Generation\nProtein 3D Graph Structure Learning for Robust Structure-Based Protein Property Prediction\nDual-Channel Learning Framework for Drug-Drug Interaction Prediction via Relation-Aware Heterogeneous Graph Transformer\nGxVAEs: Two Joint VAEs Generate Hit Molecules from Gene Expression Profile\nPSC-CPI: Multi-Scale Protein Sequence-Structure Contrasting for Efficient and Generalizable Compound-Protein Interaction Prediction\nA Multi-Modal Contrastive Diffusion Model for Therapeutic Peptide Generation\nRegulating AI: Applying Insights from Behavioural Economics and Psychology to the Application of Article 5 of the EU AI Act\n\nPlease visit the AAAI-24 Conference website for more information and to register.
URL:https://globalbiodefense.com/event/the-38th-annual-aaai-conference-on-artificial-intelligence/
LOCATION:Vancouver Convention Center\, 1055 Canada Pl\, Vancouver\, British Columbia\, V6C 0C3\, Canada
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Zurich:20240220T090000
DTEND;TZID=Europe/Zurich:20240220T103000
DTSTAMP:20240219T010614Z
CREATED:20240219T010514Z
LAST-MODIFIED:20240219T010614Z
UID:60060-1708419600-1708425000@globalbiodefense.com
SUMMARY:CIABT and Biological Risks
DESCRIPTION:Advances in biotechnology generate new opportunities\, but also create certain risks in terms of dual use of biological and toxin agents and with respect to compliance with the 1972 Convention on the Prohibition of Biological Weapons (CIABT). \nThis is the first event in a series of French-speaking meetings on disarmament in 2024 which will present the CIABT and provide a more in-depth analysis of contemporary biological risks\, including in relation to artificial intelligence and cyber. The event will also provide insight into the ongoing work of the CIABT Working Group established by the 9th Review Conference in November 2022. \nThe event is open to all interested participants. The United Nations Institute for Disarmament Research (UNIDIR) encourages the participation of French-speaking representatives and experts specialized in or interested in issues related to CIABT and/or biological risks. This event will take place in French. No interpretation into other UN languages ​​will be provided. \nPROGRAMME \n\nWelcome Address: Dr. Robin Geiss \, Director\, UNIDR\nIntroductory remarks : Mr. Guillaume Ollagnier \, Director of Strategic Affairs\, Security and Disarmament at the Ministry of Europe and Foreign Affairs of France\, and HE Camille Petit \, Permanent Representative of France to the Conference on Disarmament\nPresentation of the CIABT : Mr. Remi Bacouillard \, Political Affairs Officer\, CIABT Implementation Support Unit\, Office for Disarmament Affairs (UNODA)\nOverview of scientific and technological advances : Dr. Anna Laura Ross \, Head of the Emerging Technologies Unit of the Division of Science of the World Health Organization (WHO)\, and Ms. Louison Mazeaud \, Associate Researcher\, Weapons Program mass destruction\, UNIDIR\nPerspectives on the ongoing work of the CIABT Working Group : Ms. Barbara Belkior \, Minister-Counsellor\, Permanent Representation of Brazil to the Conference on Disarmament\nConcluding remarks : HE Salomon Eheth\, Permanent Representative of Cameroon to the United Nations Office and other international organizations in Geneva\n\nThe event will be moderated by the Permanent Observer of the International Organization of la Francophonie (OIF) to the United Nations Office in Geneva\, HE Henri Monceau. \nPlease visit the UNIDR website for registration.
URL:https://globalbiodefense.com/event/ciabt-and-biological-risks/
LOCATION:Palais des Nations\, 1211 Geneva 10\, Geneva\, Switzerland
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Los_Angeles:20240220T120000
DTEND;TZID=America/Los_Angeles:20240220T130000
DTSTAMP:20240202T212828Z
CREATED:20240202T212828Z
LAST-MODIFIED:20240202T212828Z
UID:59865-1708430400-1708434000@globalbiodefense.com
SUMMARY:Threat-Agnostic Biodefense: Assessing the Zoonotic Risk of Pre-emergent Viruses
DESCRIPTION:The Pacific Northwest National Laboratory will host a webinar on “Assessing the Zoonotic Risk of Pre-emergent Viruses” on 20 February 2024 as part of the the Advancing Threat Agnostic Biodefense Webinar Series. \nThese webinars bring together like-minded science and policy members of the biodefense community to discuss relevant research activities as well as barriers and enablers of a threat agnostic approach. \nFeatured speaker: Tony Goldberg\, PhD\, Professor\, School of Veterinary Medicine\, University of Wisconsin-Madison \nExploration of the “virosphere” is in its golden age. The sheer number of new viruses discovered daily\, and the fact that most cannot be cultured\, creates enormous about where to allocate attention and resources. It is not an intractable problem\, however\, to distinguish those few viruses that are likely to emerge as zoonoses from the many others that are not. \nThis talk describes two diametric approaches to addressing this problem. The first approach involves a field-to-lab investigative methodology that\, when combine with biologically informed predictive computational models\, can assess the zoonotic risk of viruses that have not yet been identified in humans. \nThe second approach relies on the power of modern methods in anthropology and ethnography to identify zoonotic transmission pathways\, even before the identification of any pathogens that might traverse those pathways. A unifying example is simian hemorrhagic fever virus and its relatives in the family Arteriviridae\, which cause important animal diseases but have never been documented to infect humans. Both approaches identify these viruses as high-risk pre-emergent zoonoses. \nPlease visit PNNL for more information and to register.
URL:https://globalbiodefense.com/event/threat-agnostic-biodefense-assessing-the-zoonotic-risk-of-pre-emergent-viruses/
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240222T090000
DTEND;TZID=America/New_York:20240222T160000
DTSTAMP:20240202T211124Z
CREATED:20240202T210750Z
LAST-MODIFIED:20240202T211124Z
UID:59861-1708592400-1708617600@globalbiodefense.com
SUMMARY:PACCARB Public Meeting
DESCRIPTION:The 24th Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB) public meeting will be held virtually on February 22\, 2024. \nThis will be the second of two meetings to address the task provided to the PACCARB by the Secretary of HHS to address antimicrobial resistance globally. The focus of the meeting will be on international implementers and the gaps\, challenges\, and opportunities they see to combat AMR globally – specifically focusing on low- and middle-income countries. \nMeetings of the PACCARB are open to the public\, and virtual meetings can be accessed through the webcast. Registration to attend is not required but is encouraged. Attendees may also directly address the council on topics of antimicrobial resistance during public meetings. To provide written comments\, please e-mail your comments to CARB@hhs.gov. Written comments must be sent in by midnight February 15\, 2024 and should be limited to no more than one page. All public comments received prior to the deadline will be provided to the PACCARB council members. \nMeeting times are tentative and subject to change. Please visit HHS’ PACCARB website for the most current information.
URL:https://globalbiodefense.com/event/paccarb-public-meeting/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240223
DTEND;VALUE=DATE:20240224
DTSTAMP:20240218T175243Z
CREATED:20240218T174811Z
LAST-MODIFIED:20240218T175243Z
UID:60021-1708646400-1708732799@globalbiodefense.com
SUMMARY:Rapid Access to Products in Development (RAPID) Virtual Industry Day
DESCRIPTION:A Joint Industry Day for the Rapid Access to Products in Development (RAPID) program to be held virtually on 23 Feb 2024. \nThe Joint Program Executive Office for Chemical\, Biological\, Radiological\, and Nuclear Defense\, Enabling Biotechnologies (JPEO-CBRND-EB)\, develops\, manufactures and delivers safe and effective Medical Countermeasures (MCMs) for preparedness\, prevention\, protection\, response\, and recovery from CBRN threats. \nThe Rapid Access to Products in Development (RAPID) program is an integrated defense system composed of both physical MCM storage and fielding capabilities and a readily accessible information warehouse and sharing system (the RAPID Database). \nThe purpose of this Industry Day is to identify industry partners and capabilities to develop a RAPID Database capable of storing and organizing complex data and information related to CBRN MCMs such that it is intuitively accessible by a variety of end users during urgent planning and response situations. \nThe Database is intended to provide actionable information to assist CCMD-level decision makers when evaluating a RAPID MCM for potential administration to US warfighters; and JPEO- and CBDP-level decision makers when determining portfolio investment strategies or rapid response adjustments based on changing circumstances. \nThis Industry Day will include presentation by JPL EB as well as opportunities for industry partners to present their capabilities in one-on-one breakout sessions with representatives from the Government agencies. Industry partners will update Government stakeholders\, partners\, and end users on current efforts and capabilities. \nCompanies that wish to attend must register no later than 19 Feb 2024. More information is available at SAM.gov Notice ID W911SR-24-S-RAPID.
URL:https://globalbiodefense.com/event/medical-countermeasures-rapid-access-to-products-in-development-rapid-virtual-industry-day/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240224
DTEND;VALUE=DATE:20240229
DTSTAMP:20240202T041837Z
CREATED:20240202T041825Z
LAST-MODIFIED:20240202T041837Z
UID:59826-1708732800-1709164799@globalbiodefense.com
SUMMARY:Pittcon 2024
DESCRIPTION:Pittcon 2024 will be held 24-28 February 2024 in San Diego\, California. \nThis 75th edition of the Pittsburgh Conference on Analytical Chemistry and Applied Spectroscopy (Pittcon) is for anyone who develops\, buys\, or sells laboratory equipment\, performs physical or chemical analyses\, develops analysis methods\, or manages these scientists. \nPittcon is a dynamic\, international conference and exposition on laboratory science\, a venue for presenting the latest advances in analytical research and scientific instrumentation\, and a platform for continuing education and science-enhancing opportunity. \nHighlighted agenda and short course topics include: \n\nPoint-of-use Raman spectroscopic characterization of pathogens\nThermally Robust Biomimetic Substitutes to Metalloenzymes for Rapid Hydrolytic Degradation and Electrochemical Field Detection of Chemical Warfare Agents\nStrategy and Instrumentation for Safety Protection of Personnel Working on Ships for Maritime Chemical Threat Assessment and Response\nChemical Spill and Chemical Fires in East Palestine\, Ohio: Chemical Fate and Exposure Pathways\nField-deployable Biosensors for Rapid Characterization of Microbiomes\nNuclear Forensics: Analytical Chemistry Combating Nuclear Terrorism\nLabel-Free Lab on a Chip Device for Purification and Characterization of Small Extracellular Vesicles\nFighting Bacteria with Micromotors\nTargeted and Untargeted Analysis for Rapid Response Following Disasters\nOvercoming Challenges in Pharmaceutical Development Using Novel Analytical Approaches\nApplication of 2DLC to novel therapeutics\nModified Membranes for Rapid Monoclonal Antibody Capture\, Digestion\, and Analysis\nBiomarker Detection using Microfluidics\nHandheld Near-Infrared Spectroscopy: Anywhere\, Anytime by Anybody\nIntroduction to Quantitative Spectroscopy for Near Infrared and Raman Instrumentation\nIntroduction to Solid State NPR Spectroscopy\nFundamentals and Recent Developments of X-Ray Photoelectron Spectroscopy\nThe Art of Structure Elucidation of Small Molecules Using Mass Spectrometry\nIndustrial Problem-Solving Using Surface FTIR Techniques\nEffective Technical Communication for Analytical Chemists\nMethod Translation and Modelling in Gas Chromatography\nThermal Gel Electrophoresis to Streamline Biological Characterizations\n\nPlease visit the Pittcon 2024 website for more information and to register to attend.
URL:https://globalbiodefense.com/event/pittcon-2024/
LOCATION:San Diego Convention Center\, 111 West Harbor Drive\, San Diego\, CA 92101\, 92101\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20240224T190000
DTEND;TZID=America/New_York:20240224T213000
DTSTAMP:20240202T001437Z
CREATED:20240202T001437Z
LAST-MODIFIED:20240202T001437Z
UID:59824-1708801200-1708810200@globalbiodefense.com
SUMMARY:An Enemy of the People: A Public Health Project
DESCRIPTION:LabX – a program of the National Academy of Sciences – in partnership with Cultural Programs of the NAS\, present An Enemy of the People\, featuring performances by acclaimed actors David Strathairn (Nomadland)\, Keith David (Nope)\, Brían F. O’Byrne (The Wonder)\, and Jay O. Sanders (True Detective) as well as public health leaders Anthony Fauci (Former Director\, National Institute of Allergy and Infectious Diseases)\, Francis Collins (Former Director\, National Institutes of Health)\, Keshia Pollack Porter (Chair\, Department of Health Policy and Management\, Johns Hopkins Bloomberg School of Public Health)\, Gloria Addo-Ayensu (Director of Health\, Fairfax County Health Department)\, Ruth Faden (Founder\, Johns Hopkins Institute of Bioethics)\, Victor Dzau (President\, National Academy of Medicine)\, Nancy Kass (Deputy Director of Public Health at the Johns Hopkins Institute of Bioethics)\, Vivian Pinn (Senior Scientist Emerita at the NIH Fogarty International Center) and more! \nTogether they will perform dramatic readings of scenes from Henrik Ibsen’s 1882 play An Enemy of the People to help frame powerful\, guided audience discussions aimed at generating connection\, understanding\, compassion\, moral repair\, and much-needed healing. \nAn Enemy of the People tells the story of a doctor who discovers the water supply in his small\, rural town has been poisoned by a tannery. Despite his efforts to convey the truth to the public\, the doctor fails to save his community from environmental disaster and is ultimately scapegoated for his whistleblowing. An Enemy of the People was first performed in Norway in 1882\, and yet it speaks to the present moment as if it were written for our times — to the corrosive influence of power and money in politics\, the distortions of the media\, and the many other challenges to public health in our culture today\, especially during times of crisis. \nJoin NAS for an evening of profound exploration\, thought-provoking dialogue\, and shared intellectual engagement. \nPresented by Theater of War Productions and LabX – A Program of the National Academy of Sciences in partnership with Cultural Programs of the National Academy of Sciences. Adapted\, directed\, and facilitated by Bryan Doerries. \nPlease visit the National Academies’ An Enemy of the People: A Public Health Project to register to attend.
URL:https://globalbiodefense.com/event/an-enemy-of-the-people-a-public-health-project/
LOCATION:National Academies of Sciences\, 2101 Constitution Ave NW\, Washington\, DC\, 20418\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20240228
DTEND;VALUE=DATE:20240301
DTSTAMP:20240226T215053Z
CREATED:20240226T215042Z
LAST-MODIFIED:20240226T215053Z
UID:60125-1709078400-1709251199@globalbiodefense.com
SUMMARY:Meeting of the Advisory Committee on Immunization Practices (ACIP)
DESCRIPTION:The CDC’s Advisory Committee on Immunization Practices (ACIP) will convene 28-29 February 2024 in Atlanta\, GA and via webcast. \nThe ACIP develops recommendations for U.S. immunizations\, including ages when vaccines should be given\, number of doses\, time between doses\, and precautions and contraindications. \nThe agenda will include the following: \n\nUpdate on chikungunya vaccine licensure and review of proposed policy options for chikungunya vaccine use among U.S. adults traveling abroad\, laboratory workers\, and pregnant and breastfeeding persons\nGuidance to use Td vaccine for those instances when receipt of the pertussis component is contraindicated\nCOVID-19 vaccination coverage\, effectiveness and economic analysis of additional dose recommendations\nNext steps for the COVID-19 vaccine program\nInterim estimates of 2023-24 seasonal influenza vaccine effectiveness\nSafety of LAIV4 in children with asthma\nInfluenza B/Yamagata update\nPolio Work Group deliberations on potential use of nOPV2 as an outbreak control measure in the US\nClinical considerations for children who received fractional dose inactivated polio vaccine (fIPV) in other countries\nPost-marketing safety surveillance of older adult RSV vaccination\nPreliminary Analysis of Guillain-Barré Syndrome (GBS) following RSV vaccination among adults 65 years and older\nOverview of Moderna’s investigational RSV Vaccine (mRNA-1345) in adults ≥60 years of age\nRevising the adolescent Meningococcal vaccine schedule\nCurrent epidemiology of invasive pneumococcal disease and pneumococcal vaccine coverage in adults\nPreliminary findings of the Pneumococcal pNeumonia Epidemiology\, Urine serotyping\, and Mental Outcomes (PNEUMO) US study\nBackground on invasive Hib disease and vaccination among American Indian and Alaska Native Populations\n\nThe meeting will be held on February 28\, 2024\, from 8 a.m. to 5 p.m.\, EST and February 29\, 2024\, from 8 a.m.\nto 3 p.m.\, EST (times subject to change). \nPlease visit the CDC’s Advisory Committee on Immunization Practices for the latest information. No registration is required to watch the webcasts.
URL:https://globalbiodefense.com/event/meeting-of-the-advisory-committee-on-immunization-practices-acip/
CATEGORIES:Government Hosted
LOCATION:https://video.ibm.com/channel/VWBXKBR8af4
END:VEVENT
END:VCALENDAR